Antibodies, detection systems and accessories for immunohistology
Probes, kits and detection systems – visualizing DNA and RNA in tissue sections
Real-time PCR, Next Generation Sequencing (NGS) and DNA arrays – careful analysis, reliable detection
Semi-automated immunostaining systems – for maximum flexibility, highest staining quality and high throughput
Complete blocks, slide sets and individual tissue arrays – for routine and research
We are a Berlin-based company specializing in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in situ hybridization and molecular pathology.
Consistent high quality is a top priority. This is why development and manufacturing of our products are governed by a quality management system certified to ISO 9001:2015 and ISO 13485:2016. A majority of the Zytomed Systems products are CE labelled and are approved as reagents for in vitro purposes (CE/IVD). See the download section for our certificates.
At Zytomed Systems we will be also compliant with the IVDR requirements.
Learn moreEthically correct, respectful dealing with our business partners is of very high importance to Zytomed Systems GmbH and a matter of course. This includes all commercial, legal and interpersonal levels, concerns and aspects.
Learn moreThanks to our extensive network of distribution partners, you can order our products from anywhere in the world. The high degree of satisfaction of our customers speaks for itself. Our aim is to precisely tailor our products to your needs. Rely on our many years of experience, our quality, flexibility and excellent service.
Learn morePRAME is found in primary and metastatic melanoma. Immunohistochemical stainings show mostly diffuse positive tumor tissue. Since normal skin is usually negative for PRAME, detection of PRAME protein is useful to determine tumor margin and to differentiate between melanocytic nevi and melanoma.
CE/IVD-labelled clone EPR20330 anti-PRAME: Available at Zytomed Systems!
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).
With the entry into force of the "In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746" on May 26, 2022, the future use of so-called "laboratory developed tests" (LDTs) or in-house IVDs will also be regulated. According to the Article 5(5), LDTs of health institutions must comply with the essential safety and performance requirements set out in Annex I.
Contact us! Within the scope of our IHC workshops, we will be pleased to inform you about the above and further requirements for you as a manufacturer of LDTs.
Your Immunohistochemistry Product Management Team
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC.